Self-complementary adeno-associated virus-mediated interleukin-1 receptor antagonist gene delivery for the treatment of osteoarthritis: Test of efficacy in an equine model

Rachael S. Watson Levings, Andrew D. Smith, Ted A. Broome, Brett L. Rice, Eric P. Gibbs, David A. Myara, E. Viktoria Hyddmark, Elham Nasri, Ali Zarezadeh, Padraic P. Levings, Yuan Lu, Margaret E. White, E. Anthony Dacanay, Gregory B. Foremny, Christopher H. Evans, Alison J. Morton, Mathew Winter, Michael J. Dark, David M. Nickerson, Patrick T. ColahanSteven C. Ghivizzani

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The authors are investigating self-complementary adeno-associated virus (scAAV) as a vector for intra-articular gene-delivery of interleukin-1 receptor antagonist (IL-1Ra), and its therapeutic capacity in the treatment of osteoarthritis (OA). To model gene transfer on a scale proportional to the human knee, a frequent site of OA incidence, studies were focused on the joints of the equine forelimb. Using AAV2.5 capsid and equine IL-1Ra as a homologous transgene, a functional ceiling dose of ∼5 × 1012 viral genomes was previously identified, which elevated the steady state levels of eqIL-1Ra in synovial fluids by >40-fold over endogenous production for at least 6 months. Here, using an osteochondral fragmentation model of early OA, the functional capacity of scAAV.IL-1Ra gene-delivery was examined in equine joints over a period of 12 weeks. In the disease model, transgenic eqIL-1Ra expression was several fold higher than seen previously in healthy joints, and correlated directly with the severity of joint pathology at the time of treatment. Despite wide variation in expression, the steady-state eqIL-1Ra in synovial fluids exceeded that of IL-1 by >400-fold in all animals, and a consistent treatment effect was observed. This included a 30-40% reduction in lameness and ∼25% improvement in total joint pathology by both magnetic resonance imaging and arthroscopic assessments, which included reduced joint effusion and synovitis, and improved repair of the osteochondral lesion. No vector-related increase in eqIL-1Ra levels in blood or urine was noted. Cumulatively, these studies in the equine model indicate scAAV.IL-1Ra administration is reasonably safe and capable of sustained therapeutic IL-1Ra production intra-articularly in joints of human scale. This profile supports consideration for human testing in OA.

Original languageEnglish (US)
Pages (from-to)101-112
Number of pages12
JournalHuman Gene Therapy Clinical Development
Volume29
Issue number2
DOIs
StatePublished - Jun 2018

Keywords

  • AAV
  • IL-1Ra
  • arthritis
  • gene therapy
  • osteoarthritis
  • osteoarthritis gene therapy

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Self-complementary adeno-associated virus-mediated interleukin-1 receptor antagonist gene delivery for the treatment of osteoarthritis: Test of efficacy in an equine model'. Together they form a unique fingerprint.

  • Cite this

    Watson Levings, R. S., Smith, A. D., Broome, T. A., Rice, B. L., Gibbs, E. P., Myara, D. A., Hyddmark, E. V., Nasri, E., Zarezadeh, A., Levings, P. P., Lu, Y., White, M. E., Dacanay, E. A., Foremny, G. B., Evans, C. H., Morton, A. J., Winter, M., Dark, M. J., Nickerson, D. M., ... Ghivizzani, S. C. (2018). Self-complementary adeno-associated virus-mediated interleukin-1 receptor antagonist gene delivery for the treatment of osteoarthritis: Test of efficacy in an equine model. Human Gene Therapy Clinical Development, 29(2), 101-112. https://doi.org/10.1089/humc.2017.143